ADC Therapeutics (ADCT)

Executive Summary

ADC Therapeutics is a commercial-stage Swiss biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment. Its lead product, ZYNLONTA® (loncastuximab tesirine), is FDA-approved for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and generates revenue. The company leverages its proprietary PBD-based linker-payload technology to enhance efficacy and reduce toxicity. ADC Therapeutics is focused on expanding ZYNLONTA's label into additional hematologic indications and advancing early-stage pipeline candidates for solid tumors and lymphomas. Despite a challenging competitive landscape, the company's validated platform and approved product provide a foundation for growth, though financial sustainability remains a concern due to dependence on ZYNLONTA sales and ongoing R&D costs.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 intermediate data for loncastuximab tesirine in marginal zone lymphoma (NCT05296070)40% success
• H1 2027Phase 1 data for loncastuximab tesirine + rituximab in central nervous system lymphoma (NCT06607549)30% success
• 2027Potential ZYNLONTA label expansion into earlier lines of therapy or new indications25% success